NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it has signed an agreement making Cytolog Laboratories the exclusive distributor of its RosettaGX Reveal thyroid test in Brazil.
Reveal is a microRNA-based assay used to classify indeterminate thyroid nodules. Under the terms of the deal, Cytolog will have the exclusive right to sell and market the test in Brazil. Additional terms were not disclosed.
"We are particularly pleased to expand access for Reveal to the Brazilian market where the incidence of thyroid cancer diagnosis is growing," Rosetta President and CEO Kenneth Berlin said in a statement. "Unlike other assays in the space, Reveal does not require fresh tissue and therefore does not require special logistics for sample handling and shipment."
Rosetta said that Cytolog already has regulatory approvals to send biological samples outside of Brazil and that it expects to begin offering Reveal immediately.
"This is our first distribution agreement in South America and it marks a significant milestone in our strategic goal to expand global access for Reveal," Berlin added. Earlier this week, Rosetta announced that it has realigned its business strategy to focus on the test.